{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Empagliflozin+Arm&page=2",
    "query": {
      "intervention": "Empagliflozin Arm",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 32,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Empagliflozin+Arm&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Empagliflozin+Arm&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-03T03:01:22.948Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03852901",
      "title": "Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Empaglifozin",
        "Physiological Effects of Drugs",
        "Hypoglycemic Agents",
        "Sodium-Glucose Transporter 2 Inhibitors"
      ],
      "interventions": [
        {
          "name": "empagliflozin (Jardiance) 25 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute on Aging (NIA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2019-03-28",
      "completion_date": "2021-12-13",
      "has_results": true,
      "last_update_posted_date": "2022-08-02",
      "last_synced_at": "2026-10-03T03:01:22.948Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03852901"
    },
    {
      "nct_id": "NCT05512130",
      "title": "Sodium-Glucose Cotransporter-2 Inhibitors: A Potential Novel Treatment for Epilepsy",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "Empagliflozin 25 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 18,
      "start_date": "2022-08-17",
      "completion_date": "2023-06-30",
      "has_results": false,
      "last_update_posted_date": "2022-08-23",
      "last_synced_at": "2026-10-03T03:01:22.948Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05512130"
    },
    {
      "nct_id": "NCT05885074",
      "title": "Mechanistic Insights to Weight Loss Maintenance Through SGLT2 Inhibitors",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity",
        "Weight Loss"
      ],
      "interventions": [
        {
          "name": "Empagliflozin Arm",
          "type": "DRUG"
        },
        {
          "name": "Control Arm",
          "type": "OTHER"
        },
        {
          "name": "Exercise capacity VO2 maximum determination",
          "type": "OTHER"
        },
        {
          "name": "Exercise Challenge",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2025-01-30",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2024-08-07",
      "last_synced_at": "2026-10-03T03:01:22.948Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05885074"
    },
    {
      "nct_id": "NCT03152552",
      "title": "A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus and Heart Failure"
      ],
      "interventions": [
        {
          "name": "LIK066",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 125,
      "start_date": "2017-07-25",
      "completion_date": "2018-06-06",
      "has_results": true,
      "last_update_posted_date": "2019-08-28",
      "last_synced_at": "2026-10-03T03:01:22.948Z",
      "location_count": 21,
      "location_summary": "Huntsville, Alabama • Carmichael, California • Concord, California + 18 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Carmichael",
          "state": "California"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03152552"
    },
    {
      "nct_id": "NCT06355310",
      "title": "Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Alcoholic Fatty Liver Disease"
      ],
      "interventions": [
        {
          "name": "Empagliflozin 10 MG",
          "type": "DRUG"
        },
        {
          "name": "Placebo Oral Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Justin Ryder",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "16 Years to 20 Years"
      },
      "enrollment_count": 40,
      "start_date": "2025-04-10",
      "completion_date": "2028-02-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-21",
      "last_synced_at": "2026-10-03T03:01:22.948Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06355310"
    },
    {
      "nct_id": "NCT05013502",
      "title": "Empagliflozin in Diuretic Refractory Ascites",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Liver Cirrhosis",
        "Cirrhosis",
        "Ascites",
        "Ascites Hepatic",
        "Sodium-Glucose Transporter 2 Inhibitors"
      ],
      "interventions": [
        {
          "name": "Empagliflozin 10 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 14,
      "start_date": "2021-11-15",
      "completion_date": "2023-06-30",
      "has_results": false,
      "last_update_posted_date": "2023-08-02",
      "last_synced_at": "2026-10-03T03:01:22.948Z",
      "location_count": 1,
      "location_summary": "Redwood City, California",
      "locations": [
        {
          "city": "Redwood City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05013502"
    },
    {
      "nct_id": "NCT05254002",
      "title": "A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus",
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Finerenone (BAY94-8862 ) 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin Placebo",
          "type": "DRUG"
        },
        {
          "name": "Finerenone (BAY94-8862 ) 20 mg",
          "type": "DRUG"
        },
        {
          "name": "Finerenone Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1664,
      "start_date": "2022-06-23",
      "completion_date": "2025-03-17",
      "has_results": true,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-10-03T03:01:22.948Z",
      "location_count": 46,
      "location_summary": "Surprise, Arizona • Los Angeles, California • Northridge, California + 36 more",
      "locations": [
        {
          "city": "Surprise",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Sylmar",
          "state": "California"
        },
        {
          "city": "Vallejo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05254002"
    },
    {
      "nct_id": "NCT01719003",
      "title": "Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2",
        "Hyperglycemia"
      ],
      "interventions": [
        {
          "name": "Metformin 500 mg bid",
          "type": "DRUG"
        },
        {
          "name": "Metformin 1000 mg bid",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin low dose qd",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin high dose qd",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin low dose bid",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin high dose bid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1413,
      "start_date": "2012-10",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2016-02-19",
      "last_synced_at": "2026-10-03T03:01:22.948Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • Manley Hot Springs, Alaska • Glendale, Arizona + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Manley Hot Springs",
          "state": "Alaska"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Searcy",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01719003"
    },
    {
      "nct_id": "NCT04505774",
      "title": "Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "theraputic heparin",
          "type": "DRUG"
        },
        {
          "name": "prophylactic heparin",
          "type": "DRUG"
        },
        {
          "name": "P2Y12",
          "type": "DRUG"
        },
        {
          "name": "Crizanlizumab Injection",
          "type": "DRUG"
        },
        {
          "name": "SGLT2 inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Matthew Neal MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3591,
      "start_date": "2020-09-04",
      "completion_date": "2024-01-26",
      "has_results": true,
      "last_update_posted_date": "2024-12-30",
      "last_synced_at": "2026-10-03T03:01:22.948Z",
      "location_count": 81,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fontana",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04505774"
    },
    {
      "nct_id": "NCT01159600",
      "title": "Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Placebo identical to BI 10773 high dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo identical to BI 10773 low dose",
          "type": "DRUG"
        },
        {
          "name": "BI 10773",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1504,
      "start_date": "2010-07",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-06-17",
      "last_synced_at": "2026-10-03T03:01:22.948Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Tempe, Arizona • Huntington Park, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01159600"
    }
  ]
}